StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX - Free Report) in a research report released on Thursday. The firm issued a sell rating on the stock.

Separately, Benchmark reiterated a hold rating on shares of VolitionRx in a report on Friday, August 16th.

VolitionRx Stock Up 9.3 %

Shares of NYSE VNRX traded up $0.06 during midday trading on Thursday, hitting $0.76. The stock had a trading volume of 255,215 shares, compared to its average volume of 168,531. The company has a market cap of $69.98 million, a P/E ratio of -1.72 and a beta of 1.12. The business's 50 day moving average is $0.64 and its 200-day moving average is $0.69. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23.

VolitionRx (NYSE:VNRX - Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. As a group, analysts expect that VolitionRx will post -0.31 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Guy Archibald Innes purchased 150,000 shares of the company's stock in a transaction dated Tuesday, August 20th. The shares were purchased at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the purchase, the director now directly owns 406,683 shares in the company, valued at approximately $272,477.61. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 12.80% of the stock is currently owned by insiders.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.